Monero (XMR) has been delisted from all major EU-authorized crypto exchanges by the end of 2024 due to EU regulations banning trading of privacy coins that conceal transaction details. From July 2027, EU anti-money laundering laws will also prohibit custody of Monero on licensed platforms, effectively banning holding it through authorized providers. Investors must withdraw or convert holdings by deadlines or face forced conversions, as seen with Kraken's prior delisting. While holding Monero in private wallets remains legal, buying or storing it via EU-authorized exchanges will no longer be possible, pushing users to unregulated platforms or direct swaps with higher risks and tax implications.
The story on buying Monero in Germany provides context for cryptocurrency market trends. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 07, 2026 04:41 WIB: out of 50 priced major cryptocurrencies, 9 rose and 40 fell today. Notable movers include EGLD at Rp79.645 with a -4.07% change and a typical hold time of 85 days, SAND at Rp1.184 with a -4.02% change and a hold time of 123 days, and ZIL at Rp63 with a -3.81% change and a hold time of 133 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
